<DOC>
	<DOCNO>NCT02372084</DOCNO>
	<brief_summary>To assess pharmacokinetics single oral dose osilodrostat ( LCI699 ) 30 mg subject mild , moderate severe hepatic impairment compare subject normal hepatic function .</brief_summary>
	<brief_title>A Phase 1 Study Osilodrostat ( LCI699 ) Healthy Volunteers Subjects With Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Weight ≥50 kg BMI 1838kg/m2 . Stable liver cirrhosis evidence hepatic impairment . ‐Free significant medical disorder unrelated underlying hepatic impairment History surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug Subjects ongoing alcohol drug abuse Symptoms history encephalopathy ( Grade 2 ) History presence liver disease liver injury ( healthy volunteer ) History presence impair renal function Clinical evidence severe ascites . Total Bilirubin &gt; 6 mg/dL , Subjects serum free cortisol test result low limit normal ( base central laboratory ) screen period Concomitant use drug strong inducer CYP3A4/5 pathway Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatic impairment ,</keyword>
	<keyword>osilodrostat ,</keyword>
	<keyword>LCI699</keyword>
</DOC>